Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Natalie Katz

Neurology with Special Qualifications in Child Neurology Durham, NC Medical Doctor

NPI 1871956896 CMS profile 1775633

3000 Erwin Rd, Durham, NC 27705

Open in the dashboard

General payments

$59,907

93 records reported · program years 2019–2025

Research payments

$2,225

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Natalie Katz of Durham, NC is reported in the CMS Open Payments database as having received $59,907 across 93 general payments and $2,225 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $39,131 59
2024 General $20,505 29
2023 General $171 3
2023 Research $2,225 5
2020 General $21 1
2019 General $80 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Natalie Katz
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Natalie Katz were reported at $39,131. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Natalie Katz Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $80 $262 $68–$1,313 $163
2020 $21 $188 $46–$1,222 $114
2021 $0 $183 $45–$1,356 $132
2022 $0 $229 $72–$1,177 $149
2023 $171 $269 $93–$1,195 $160
2024 $20,505 $300 $98–$1,428 $164
2025 $39,131 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sarepta Therapeutics, Inc. $25,521 34 payments
  2. Biogen, Inc. $11,405 21 payments
  3. ITF Therapeutics LLC $10,034 17 payments
  4. Catalyst Pharmaceuticals, Inc. $8,745 8 payments
  5. Genentech USA, Inc. $3,791 6 payments
  6. Novartis Pharmaceuticals Corporation $276 4 payments
  7. LivaNova USA, Inc. $101 2 payments
  8. Genentech, Inc. $33 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $38,204 9 payments
  2. Honoraria $12,762 7 payments
  3. Travel and Lodging $5,615 25 payments
  4. Food and Beverage $3,327 52 payments
Products named General payments · program years 2019–2025
  1. Elevidys $16,698 20 payments
  2. AGAMREE $8,745 8 payments
  3. SPINRAZA $3,929 12 payments
  4. Evrysdi $3,824 7 payments
  5. Skyclarys $610 9 payments
  6. ZOLGENSMA $252 3 payments
  7. QALSODY Als $222 2 payments
  8. VNS Therapy $101 2 payments
  9. QALSODY Neurology $80 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sarepta Therapeutics, Inc. $2,225 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

38

Median for Pediatric Medicine: 38

Drug cost

$1,132,910

Median for Pediatric Medicine: $2,769

Branded share of claims

100%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyclarys Omaveloxolone Brand 21 $683,493
Evrysdi Risdiplam Brand 17 $449,417

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPINRAZA
  • Biogen, Inc. $3,344
$3,344 — —
Skyclarys
  • Biogen, Inc. $92
$92 21 —
QALSODY
  • Biogen, Inc. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record